GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Cash Flow from Investing

ChemoCentryx (ChemoCentryx) Cash Flow from Investing : $12.53 Mil (TTM As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2022, ChemoCentryx spent $0.40 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $35.26 Mil on purchasing investments. It gained $63.74 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, ChemoCentryx gained $28.08 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2022.


ChemoCentryx Cash Flow from Investing Historical Data

The historical data trend for ChemoCentryx's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Cash Flow from Investing Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.60 -53.07 -12.53 -282.36 92.22

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.77 42.33 -36.54 -21.34 28.08

ChemoCentryx Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

ChemoCentryx's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:

ChemoCentryx's Cash Flow from Investing for the quarter that ended in Jun. 2022 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoCentryx  (NAS:CCXI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

ChemoCentryx's purchase of property, plant, equipment for the three months ended in Jun. 2022 was $-0.40 Mil. It means ChemoCentryx spent $0.40 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

ChemoCentryx's sale of property, plant, equipment for the three months ended in Jun. 2022 was $0.00 Mil. It means ChemoCentryx gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

ChemoCentryx's purchase of business for the three months ended in Jun. 2022 was $0.00 Mil. It means ChemoCentryx spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

ChemoCentryx's sale of business for the three months ended in Jun. 2022 was $0.00 Mil. It means ChemoCentryx gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

ChemoCentryx's purchase of investment for the three months ended in Jun. 2022 was $-35.26 Mil. It means ChemoCentryx spent {stock_data.stock.currency_symbol}}35.26 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

ChemoCentryx's sale of investment for the three months ended in Jun. 2022 was $63.74 Mil. It means ChemoCentryx gained $63.74 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

ChemoCentryx's net Intangibles purchase and sale for the three months ended in Jun. 2022 was $0.00 Mil. It means ChemoCentryx paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

ChemoCentryx's cash from discontinued investing activities for the three months ended in Jun. 2022 was 0.00 Mil. It means ChemoCentryx paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

ChemoCentryx's cash from other investing activities for the three months ended in Jun. 2022 was $-0.00 Mil. It means ChemoCentryx paid $0.00 Mil for other investing activities.


ChemoCentryx Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027

ChemoCentryx (ChemoCentryx) Headlines

From GuruFocus

ChemoCentryx Announces Changes to its Board of Directors

By GuruFocusNews GuruFocusNews 06-30-2022

ChemoCentryx Announces Changes to its Board of Directors

By GuruFocusNews GuruFocusNews 07-10-2022